ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $83,421 | +30.3% | 5,240 | +33.1% | 0.00% | 0.0% |
| Q3 2022 | $64,000 | +68.4% | 3,937 | +45.3% | 0.00% | +100.0% |
| Q2 2022 | $38,000 | +153.3% | 2,709 | +328.6% | 0.00% | – |
| Q1 2022 | $15,000 | -72.7% | 632 | -70.4% | 0.00% | -100.0% |
| Q1 2021 | $55,000 | -92.3% | 2,133 | -83.9% | 0.00% | -93.9% |
| Q4 2020 | $710,000 | +5.5% | 13,277 | -18.7% | 0.03% | -13.2% |
| Q3 2020 | $673,000 | +1822.9% | 16,325 | +2139.4% | 0.04% | +533.3% |
| Q2 2020 | $35,000 | -5.4% | 729 | -17.6% | 0.01% | -70.0% |
| Q1 2020 | $37,000 | – | 885 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |